疫苗诱导免疫性血小板减少症和血栓形成中的纤维蛋白原溶解与纤维蛋白溶解
本研究检测18例疑似VITT患者血浆,其中11例符合VITT标准、7例为非VITT。VITT患者10/11符合显性弥散性血管内凝血标准,纤维蛋白原和FXIII水平显著降低,PAP和tPA介导的纤溶酶生成增高,9/11可见纤维蛋白原溶解证据。结论认为VITT存在由失调的纤溶酶生成介导的显性DIC和纤维蛋白原溶解,与血栓和出血的临床表现一致。
要点
- VITT患者10/11符合显性弥散性血管内凝血标准,非VITT患者0/7符合。
- VITT患者纤维蛋白原和FXIII水平显著低于非VITT患者,PAP和tPA介导的纤溶酶生成高于非VITT患者。
- 9/11例VITT患者可见纤维蛋白原溶解证据,非VITT患者和健康对照未见。
核心结论
- VITT患者显示显性弥散性血管内凝血和纤维蛋白原溶解的证据,由失调的纤溶酶生成介导,表现为PAP和纤溶酶生成增加。
- 这些观察与VITT中血栓和出血的临床表现一致。
研究设计与样本
- 检测18例疑似VITT病例的血浆样本,以ELISA检测抗PF4抗体,11/18符合VITT标准,7/18被认为不太可能(非VITT)。
- 定量检测PAI-1、凝血因子XIII(FXIII)、纤溶酶-α2抗纤溶酶复合物(PAP)及炎症标志物的抗原水平。
- 以显色底物法量化纤溶酶生成,并用针对纤维蛋白原、FXIII-A和纤溶酶原的抗体进行蛋白质印迹。
主要发现
- VITT患者10/11符合显性弥散性血管内凝血标准,非VITT患者0/7符合。
- VITT患者炎症标志物IL-1β、IL-6、IL-8、TNFα和C反应蛋白水平显著更高。
- VITT患者纤维蛋白原和FXIII水平显著更低,而PAP和tPA介导的纤溶酶生成较非VITT患者更高。
- 9/11例VITT患者可见纤维蛋白原溶解证据,非VITT患者或健康对照未见。
- 可见纤维蛋白原降解产物,纤维蛋白原α链明显裂解;有纤维蛋白原溶解的VITT患者PAP复合物明显,非VITT患者或健康供者未见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare syndrome associated with adenoviral vector vaccines for COVID-19. The syndrome is characterized by thrombosis, anti-platelet factor 4 (PF4) antibodies, thrombocytopenia, high D-dimer, and hypofibrinogenemia. OBJECTIVES: To investigate abnormalities in fibrinolysis that contribute to the clinical features of VITT. METHODS: Plasma samples from 18 suspected VITT cases were tested for anti-PF4 by ELISA and characterized as meeting criteria for VITT (11/18) or deemed unlikely (7/18; non-VITT). Antigen levels of PAI-1, factor XIII (FXIII), plasmin-α2antiplasmin (PAP), and inflammatory markers were quantified. Plasmin generation was quantified by chromogenic substrate. Western blotting was performed with antibodies to fibrinogen, FXIII-A, and plasminogen. RESULTS: VITT patients 10/11 had scores indicative of overt disseminated intravascular coagulation, while 0/7 non-VITT patients met the criteria. VITT patients had significantly higher levels of inflammatory markers, IL-1β, IL-6, IL-8, TNFα, and C-reactive protein. In VITT patients, both fibrinogen and FXIII levels were significantly lower, while PAP and tPA-mediated plasmin generation were higher compared to non-VITT patients. Evidence of fibrinogenolysis was observed in 9/11 VITT patients but not in non-VITT patients or healthy controls. Fibrinogen degradation products were apparent, with obvious cleavage of the fibrinogen α-chain. PAP complex was evident in those VITT patients with fibrinogenolysis, but not in non-VITT patients or healthy donors. CONCLUSION: VITT patients show evidence of overt disseminated intravascular coagulation and fibrinogenolysis, mediated by dysregulated plasmin generation, as evidenced by increased PAP and plasmin generation. These observations are consistent with the clinical presentation of both thrombosis and bleeding in VITT.
引用
- Simpson M, Narwal A, West E, et al. Fibrinogenolysis and fibrinolysis in vaccine-induced immune thrombocytopenia and thrombosis. J Thromb Haemost. 2023. PMID: 37734715. doi:10.1016/j.jtha.2023.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。